Skip to main content

Qiagen Value Stock - Dividend - Research Selection


ISIN: NL0012169213 , WKN: A2DKCH

Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Key figures
Cash flow
Balance sheet
Income statement
Div. Yield%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization USD
Raw Data Source
Stock Split

Description of the company

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions. It also provides Ingenuity Variant Analysis, a cloud-based platform that interprets data from next-generation sequencing (NGS) analysis; QIAGEN Clinical Insight, an evidence-based decision support solution; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web-based portal that enables researchers to search and select gene-and pathway-specific solutions from pre-designed and custom PCR assay kits, NGS assay panels, and other products. In addition, the company offers instrumentation systems for laboratories. Its automation platforms include QIAsymphony, a modular system; GeneReader NGS System, a sample to insight NGS solution for laboratories to deliver actionable results; QIAcube robotic workstations, which provides versatile solutions for automated sample processing; QIAxcel for nucleic acid separation; QIAgility, a benchtop instrument for PCR setup; and ESEQuant instruments that enable optical measurement for point of need molecular testing in physician practices, emergency rooms, remote areas, and other applications. It serves molecular diagnostics, applied testing, pharma, and academia customers. QIAGEN N.V. has a collaboration with Bristol-Myers Squibb to develop gene expression profiles for immuno-oncology therapies. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


QIAGEN’s tuberculosis blood test QuantiFERON-TB Gold Plus gains CE-marking under new EU IVDR framework

VENLO, The Netherlands, February 14, 2023--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the certification of QuantiFERON-TB Gold Plus (QFT-Plus) – the world’s leading tuberculosis (TB) blood test – under the European Union’s 2017/746 In Vitro Diagnostic Medical Devices Regulation (IVDR) which is replacing the 98/79/EC In Vitro Diagnostic Directive (IVDD). QFT-Plus is QIAGEN’s trusted test, endorsed by the WHO, that aids in indirect detection of the bacteria that causes

Qiagen Full Year 2022 Earnings: EPS Misses Expectations

Qiagen ( NYSE:QGEN ) Full Year 2022 Results Key Financial Results Revenue: US$2.14b (down 4.9% from FY 2021). Net...

Qiagen Offers Growth And Margin Leverage Beyond The Pandemic Deceleration

Qiagen is seeing a pandemic-driven hangover in its financial results, but underlying double-digit revenue growth was ahead of expectations. Click here to read more.

QIAGEN's (QGEN) Q4 Earnings Top Estimates, Margins Down

The ongoing double-digit sales growth in the non-COVID product portfolio contributed to QIAGEN's (QGEN) Q4 revenues.

Qiagen N.V. (QGEN) Q4 2022 Earnings Call Transcript

Qiagen N.V. (NYSE:NYSE:QGEN) Q4 2022 Earnings Conference Call February 8, 2023 9:00 AM ETCompany ParticipantsJohn Gilardi - Vice President, Head of Corporate Communications & Investor...

Qiagen (QGEN) Q4 Earnings and Revenues Beat Estimates

Qiagen (QGEN) delivered earnings and revenue surprises of 12.77% and 3.57%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Strong core growth offsets dwindling COVID-19 demand for Qiagen

Medical diagnostics company Qiagen offset a sharp fall in demand for COVID-19 products at the end of the year with a strong performance in its core businesses, the company said, announcing its full-year and fourth quarter results on Tuesday.

QIAGEN Exceeds Outlook for Fourth Quarter and Full-Year 2022 With 14% CER Sales Growth in FY 2022 From Non-COVID Product Groups

VENLO, Netherlands, February 07, 2023--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the fourth quarter and full-year 2022.

Charles River Laboratories International: A Great Business At A Decent Price

Charles River Laboratories International's shares don't look all that cheap, but they aren't exactly expensive either. Click here to read why CRL stock is a Buy.

Genetic Technologies Shares Jump After Strategic Alliance With Qiagen

Genetic Technologies Limited (NASDAQ: GENE) agreed to form a strategic alliance with Qiagen NV (NYSE: QGEN) to establish and develop a 'Centre of Excellence facility in Australia. Qiagen will support the improvement of GTG capabilities through software, hardware, consumable and technical solutions. Genetic Technologies CEO Simon Morriss said it was an exciting opportunity for the company. "We are extremely excited to be forming this alliance with the regional subsidiary of such a prestigious glo